COMP <GO>
ADAG vs VRXA // PIOTROSKI F-SCORE QUALITY
Adagene Inc. (NASDAQ) VS. Veraxa Biotech AG (NASDAQ) • 15-METRIC TALLY: ADAG 1
— VRXA 1
■ METRIC PARITY
LAST: $2.29 (-8.76%) • MKT CAP: $151.3M
piotroski-score
5/9
LAST: $1.03 (-9.65%) • MKT CAP: $145.7M
piotroski-score
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ADAG VS. VRXA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ADAG | VRXA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -8.85% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 5/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.5 | 41.1 | -3.60 | VRXA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $151.3M | $145.7M | $5.6M | ADAG | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ADAG REV | VRXA REV | ADAG GROSS % | VRXA GROSS % | ADAG FCF | VRXA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $7.7M | — | — | — | -$15.7M | — |
| FY 2024 | $103.2K | — | — | — | -$29.7M | — |
| FY 2023 | $18.1M | — | — | — | -$28.5M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ADAG // BETA —
VRXA // BETA —